167 related articles for article (PubMed ID: 9264323)
1. Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.
Fischel JL; Formento P; Etienne MC; Spector T; Renée N; Milano G
Biochem Pharmacol; 1997 Jun; 53(11):1703-9. PubMed ID: 9264323
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
3. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
4. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Beck A; Etienne MC; Chéradame S; Fischel JL; Formento P; Renée N; Milano G
Eur J Cancer; 1994; 30A(10):1517-22. PubMed ID: 7833111
[TBL] [Abstract][Full Text] [Related]
5. Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Beck A; Etienne MC; Chéradame S; Fischel JL; Formento P; Guillot T; Milano G
Eur J Cancer; 1994; 30A(10):1522-6. PubMed ID: 7833112
[TBL] [Abstract][Full Text] [Related]
6. Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities.
Katona C; Tímár F; Jeney A; Fischel JL; Milano G; Pandi E; Kralovánszky J
Anticancer Drugs; 1999 Jul; 10(6):561-7. PubMed ID: 10885904
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
[TBL] [Abstract][Full Text] [Related]
8. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
9. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
Diasio RB
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
[TBL] [Abstract][Full Text] [Related]
10. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Haaz MC; Fischel JL; Formento P; Renée N; Etienne MC; Milano G
Cancer Chemother Pharmacol; 1996; 38(1):52-8. PubMed ID: 8603452
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
[TBL] [Abstract][Full Text] [Related]
13. [Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
Fischel JL; Formento P; Berlion M; Berille J; Gioanni J; Bizzari JP; Milano G
Bull Cancer; 1992; 79(1):81-90. PubMed ID: 1520955
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase.
Peters GJ; van der Wilt CL; van Groeningen CJ
Eur J Cancer; 1994; 30A(10):1408-11. PubMed ID: 7833092
[No Abstract] [Full Text] [Related]
16. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
17. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
18. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
